Furthermore, the identification of MMR-deficient endometrial carcinomas may also guide the selection of targeted therapies, such as immune checkpoint inhibitors, which have demonstrated promising results in this molecular subtype of the disease [33]. This evidence concerns the gene MRC1 and endometrial carcinoma.